CADTH recommends reimbursement of Truvada for PrEP

24 August 2016 - The recommendation comes with conditions.

The CADTH Canadian Drug Expert Committee (CDEC) recommends that emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) be reimbursed for use as pre-exposure prophylaxis (PrEP) of human immunodeficiency virus type 1 (HIV-1) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults at high risk for infection, if the following conditions are met:

  1. Provided in the context of a sexual health program by a prescriber experienced in the treatment and prevention of HIV-1 infection.

  2. Reduced price.

The PBAC rejected a submission from Gilead for Truvada for PrEP last month due to unacceptable cost effectiveness.

Read CADTH recommendation

Michael Wonder

Posted by:

Michael Wonder